330 related articles for article (PubMed ID: 21707397)
1. Structure-based quantitative structure--activity relationship modeling of estrogen receptor β-ligands.
Dong X; Hilliard SG; Zheng W
Future Med Chem; 2011 Jun; 3(8):933-45. PubMed ID: 21707397
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits.
Taha MO; Tarairah M; Zalloum H; Abu-Sheikha G
J Mol Graph Model; 2010 Jan; 28(5):383-400. PubMed ID: 19850503
[TBL] [Abstract][Full Text] [Related]
3. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
Salum Lde B; Polikarpov I; Andricopulo AD
J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
[TBL] [Abstract][Full Text] [Related]
4. Identification of the structural requirements of the receptor-binding affinity of diphenolic azoles to estrogen receptors alpha and beta by three-dimensional quantitative structure-activity relationship and structure-activity relationship analysis.
Demyttenaere-Kovatcheva A; Cronin MT; Benfenati E; Roncaglioni A; Lopiparo E
J Med Chem; 2005 Dec; 48(24):7628-36. PubMed ID: 16302803
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of estrogen receptor-beta selective ligands.
Manas ES; Unwalla RJ; Xu ZB; Malamas MS; Miller CP; Harris HA; Hsiao C; Akopian T; Hum WT; Malakian K; Wolfrom S; Bapat A; Bhat RA; Stahl ML; Somers WS; Alvarez JC
J Am Chem Soc; 2004 Nov; 126(46):15106-19. PubMed ID: 15548008
[TBL] [Abstract][Full Text] [Related]
6. Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
Zhao L; Brinton RD
J Med Chem; 2005 May; 48(10):3463-6. PubMed ID: 15887952
[TBL] [Abstract][Full Text] [Related]
7. Comparison of estrogen receptor alpha and beta subtypes based on comparative molecular field analysis (CoMFA).
Xing L; Welsh WJ; Tong W; Perkins R; Sheehan DM
SAR QSAR Environ Res; 1999; 10(2-3):215-37. PubMed ID: 10491851
[TBL] [Abstract][Full Text] [Related]
8. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F.
Wang XS; Tang H; Golbraikh A; Tropsha A
J Chem Inf Model; 2008 May; 48(5):997-1013. PubMed ID: 18470978
[TBL] [Abstract][Full Text] [Related]
10. Use of binding energy in comparative molecular field analysis of isoform selective estrogen receptor ligands.
Wolohan P; Reichert DE
J Mol Graph Model; 2004 Sep; 23(1):23-38. PubMed ID: 15331051
[TBL] [Abstract][Full Text] [Related]
11. Combining protein modeling and 6D-QSAR. Simulating the binding of structurally diverse ligands to the estrogen receptor.
Vedani A; Dobler M; Lill MA
J Med Chem; 2005 Jun; 48(11):3700-3. PubMed ID: 15916421
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity.
Compton DR; Sheng S; Carlson KE; Rebacz NA; Lee IY; Katzenellenbogen BS; Katzenellenbogen JA
J Med Chem; 2004 Nov; 47(24):5872-93. PubMed ID: 15537344
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta.
Escande A; Pillon A; Servant N; Cravedi JP; Larrea F; Muhn P; Nicolas JC; Cavaillès V; Balaguer P
Biochem Pharmacol; 2006 May; 71(10):1459-69. PubMed ID: 16554039
[TBL] [Abstract][Full Text] [Related]
14. Descriptor analysis of estrogen receptor β-selective ligands using 2-phenylquinoline, tetrahydrofluorenone and 3-hydroxy 6H-benzo[c]chromen-6-one scaffolds.
Balaji ; Muthiah R; Sabarinath ; Ramamurthy ; Chandrasekharan
J Enzyme Inhib Med Chem; 2011 Dec; 26(6):831-42. PubMed ID: 21438712
[TBL] [Abstract][Full Text] [Related]
15. QSAR study of selective ligands for the thyroid hormone receptor beta.
Liu H; Gramatica P
Bioorg Med Chem; 2007 Aug; 15(15):5251-61. PubMed ID: 17524652
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Malamas MS; Manas ES; McDevitt RE; Gunawan I; Xu ZB; Collini MD; Miller CP; Dinh T; Henderson RA; Keith JC; Harris HA
J Med Chem; 2004 Oct; 47(21):5021-40. PubMed ID: 15456246
[TBL] [Abstract][Full Text] [Related]
17. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
Martin E; Mukherjee P; Sullivan D; Jansen J
J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
[TBL] [Abstract][Full Text] [Related]
18. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
Zeng H; Zhang H
J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
[TBL] [Abstract][Full Text] [Related]
19. Multitemplate alignment method for the development of a reliable 3D-QSAR model for the analysis of MMP3 inhibitors.
Tuccinardi T; Ortore G; Santos MA; Marques SM; Nuti E; Rossello A; Martinelli A
J Chem Inf Model; 2009 Jul; 49(7):1715-24. PubMed ID: 19522467
[TBL] [Abstract][Full Text] [Related]
20. Combining 4D pharmacophore generation and multidimensional QSAR: modeling ligand binding to the bradykinin B2 receptor.
Lill MA; Vedani A
J Chem Inf Model; 2006; 46(5):2135-45. PubMed ID: 16995744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
